IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight

• ImmunityBio said it removed the referenced podcast from its website and requested removal from external platforms.
• Enhanced compliance measures will include stricter promotional review protocols and mandatory executive-level training.
• ANKTIVA, ImmunityBio’s interleukin-15-based immunotherapy, remains central to the company’s oncology strategy.

ImmunityBio Inc. (IBRX) stated on Monday that it has responded to regulatory concerns raised by the U.S. Food and Drug Administration, outlining corrective steps related to promotional content for its cancer therapy as the company seeks to reinforce compliance standards.

The company said it submitted a detailed reply to the FDA’s Office of Prescription Drug Promotion following a March 13 communication on marketing materials, including a podcast and a television advertisement. 

FDA Inquiry And ImmunityBio’s Response

ImmunityBio clarified that the advertisement in question was never released to the public and addressed issues tied to statements made in the podcast. In response, ImmunityBio removed the referenced podcast from its website and requested its deletion from external platforms hosting the content. 

“We are dedicated to maintaining a clear distinction between our investigational pipeline aspirations and the promoted indications for our approved therapies.”

-Richard Adcock, President and CEO, ImmunityBio

 ImmunityBio stock traded over 3% higher in Monday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory amid ‘low’ message volume levels. 

Strengthening Compliance Measures

The Culver City-based firm said it is introducing tighter oversight procedures, including enhanced review protocols for marketing materials, mandatory executive-level compliance training, and the addition of external regulatory advisors to evaluate future communications. These measures are intended to ensure that promotional messaging aligns with FDA standards for accuracy and balance.

The podcast in question featured founder Patrick Soon-Shiong, who was discussing long-term scientific ambitions.

The company emphasized its commitment to providing clear and compliant information about ANKTIVA, an immunotherapy designed to stimulate key immune cells that target cancer. The treatment builds on the biology of interleukin-15 to enhance the immune response, forming part of ImmunityBio’s broader oncology strategy.

IBRX stock has gained over 268% year-to-date. 

Also See: SLNO Stock Soars Over 39% — What’s Fueling The Rally?

For updates and corrections, email newsroom[at]stocktwits[dot]com.